Patents by Inventor Clifton Dalgard

Clifton Dalgard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors for ERG oncogene positive cancers
    Patent number: 9782394
    Abstract: Alterations to the ERG gene are some of the most prominent genomic changes associated with many cancers including prostate cancer. Such cancer specific alterations result in the overexpression of wild type ERG protein or an altered ERG protein. The present invention provides selective inhibitors of wild type or an altered ERG protein expression. The ERG inhibitors of the invention, therefore, are therapeutic agents for treating ERG positive cancers.
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: October 10, 2017
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Clifton Dalgard, Ahmed Mohamed, Meera Srivastava, Shiv Srivastava
  • NOVEL INHIBITORS FOR ERG ONCOGENE POSITIVE CANCERS
    Publication number: 20170071920
    Abstract: Alterations to the ERG gene are some of the most prominent genomic changes associated with many cancers including prostate cancer. Such cancer specific alterations result in the overexpression of wild type ERG protein or an altered ERG protein. The present invention provides selective inhibitors of wild type or an altered ERG protein expression. The ERG inhibitors of the invention, therefore, are therapeutic agents for treating ERG positive cancers.
    Type: Application
    Filed: March 12, 2015
    Publication date: March 16, 2017
    Inventors: Clifton DALGARD, Ahmed MOHAMED, Meera SRIVASTAVA, Shiv SRIVASTAVA
  • Activation of hypoxia-inducible gene expression
    Publication number: 20070173545
    Abstract: The present invention relates to the elucidation of specific molecular features of endogenous 2-oxoacid molecules and their derivatives for activating hypoxia-inducible gene expression by inactivating hypoxia-inducible factor hydroxylating enzymes. This invention identifies agents that can be used to induce tissue vascularization, treat anemias, induce tolearance to stroke and heart attacks, improve tissue healing and improve organ transplantation.
    Type: Application
    Filed: November 8, 2004
    Publication date: July 26, 2007
    Inventors: Ajay Verma, Huasheng Lu, Robert Forbes, Clifton Dalgard, Ahmed Mohyeldin, Ronald Zenk